INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are elevated for 2-4 weeks after minimally invasive colorectal resection (MICR). VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2. Soluble receptors (sVEGFR1, sVEGFR2) sequester VEGF in the blood and decrease VEGF's proangiogenic effect. The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications. METHODS: Blood samples were taken (n=39) preoperatively (preop) and on postoperative days (POD) 1 and 3; in most cases a fourth sample was drawn between POD 7 and 30. sVEGFR1 and sVEGFR2 levels were measured via enzyme-linked immunosorbent assay (ELISA), which detects free and VEGF bound soluble receptor. Late samples were bundled into POD 7-13 and POD 14-30 time points. Results are reported as mean and standard deviation. The data was assessed with paired-samples t-test. RESULTS: Preop, mean plasma sVEGFR2 level (9,203.7+/-1,934.3 pg/ml) was significantly higher than the sVEGFR1 value (132.5+/-126.2 pg/ml). sVEGFR2 levels were significantly lower on POD 1 (6,957.8+/-1,947.7 pg/ml,) and POD 3 (7,085.6+/-2,000.2 pg/ml), whereas sVEGFR1 levels were significantly higher on POD 1 (220.0+/-132.8 pg/ml) and POD 3 (182.7+/-102.1 pg/ml) versus preop results. No differences were found on POD 7-13 or 14-30. CONCLUSIONS: sVEGFR2 values decreased and sVEGFR1 levels increased early after MICR; due to its much higher baseline, the sVEGFR2 changes dominate. The net result is less VEGF bound to soluble receptor and more free plasma VEGF.
INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are elevated for 2-4 weeks after minimally invasive colorectal resection (MICR). VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2. Soluble receptors (sVEGFR1, sVEGFR2) sequester VEGF in the blood and decrease VEGF's proangiogenic effect. The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications. METHODS: Blood samples were taken (n=39) preoperatively (preop) and on postoperative days (POD) 1 and 3; in most cases a fourth sample was drawn between POD 7 and 30. sVEGFR1 and sVEGFR2 levels were measured via enzyme-linked immunosorbent assay (ELISA), which detects free and VEGF bound soluble receptor. Late samples were bundled into POD 7-13 and POD 14-30 time points. Results are reported as mean and standard deviation. The data was assessed with paired-samples t-test. RESULTS: Preop, mean plasma sVEGFR2 level (9,203.7+/-1,934.3 pg/ml) was significantly higher than the sVEGFR1 value (132.5+/-126.2 pg/ml). sVEGFR2 levels were significantly lower on POD 1 (6,957.8+/-1,947.7 pg/ml,) and POD 3 (7,085.6+/-2,000.2 pg/ml), whereas sVEGFR1 levels were significantly higher on POD 1 (220.0+/-132.8 pg/ml) and POD 3 (182.7+/-102.1 pg/ml) versus preop results. No differences were found on POD 7-13 or 14-30. CONCLUSIONS: sVEGFR2 values decreased and sVEGFR1 levels increased early after MICR; due to its much higher baseline, the sVEGFR2 changes dominate. The net result is less VEGF bound to soluble receptor and more free plasma VEGF.
Authors: J Rak; Y Mitsuhashi; C Sheehan; A Tamir; A Viloria-Petit; J Filmus; S J Mansour; N G Ahn; R S Kerbel Journal: Cancer Res Date: 2000-01-15 Impact factor: 12.701
Authors: M Detmar; K T Yeo; J A Nagy; L Van de Water; L F Brown; B Berse; B M Elicker; S Ledbetter; H F Dvorak Journal: J Invest Dermatol Date: 1995-07 Impact factor: 8.551
Authors: A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan Journal: Surg Endosc Date: 2008-01-18 Impact factor: 4.584
Authors: H M C Shantha Kumara; I Kirman; D Feingold; V Cekic; A Nasar; T Arnell; E Balik; A Hoffman; R Baxter; S Conte; R L Whelan Journal: Eur J Surg Oncol Date: 2008-09-07 Impact factor: 4.424
Authors: H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan Journal: Surg Endosc Date: 2010-12-24 Impact factor: 4.584
Authors: H M C Shantha Kumara; J C Cabot; A Hoffman; M Luchtefeld; M F Kalady; N Hyman; D Feingold; R Baxter; R L Whelan Journal: Surg Endosc Date: 2009-06-24 Impact factor: 4.584
Authors: Ewa Kopczyńska; Maciej Dancewicz; Janusz Kowalewski; Roman Makarewicz; Hanna Kardymowicz; Agnieszka Kaczmarczyk; Tomasz Tyrakowski Journal: ISRN Oncol Date: 2012-03-26
Authors: J M Ou; Z Y Yu; M K Qiu; Y X Dai; Q Dong; J Shen; X F Wang; Y B Liu; Z W Quan; Z W Fei Journal: Eur J Histochem Date: 2014-03-17 Impact factor: 3.188